Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics announced it will present updated clinical data from all three of its radiopharmaceutical programs at the 2026 ASCO Annual Meeting. Key highlights include one new responder in the [212Pb]VMT01 melanoma monotherapy cohort (29% response rate), advancement of [212Pb]PSV359 to Cohort 3 with favorable safety profile, and continued deepening of responses in [212Pb]VMT-α-NET for neuroendocrine tumors. All programs demonstrated good tolerability with no dose-limiting toxicities reported.

05/21/2026, 5:51 PM • GlobeNewswire

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight

The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.

04/20/2026, 1:00 PM • GlobeNewswire

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a first-in-class 212Pb-radiopharmaceutical targeting SSTR2-positive neuroendocrine tumors. The trial showed a 43% objective response rate in Cohort 2 patients, with no dose-limiting toxicities or serious treatment-related complications. The company plans to submit clinical evidence for regulatory engagement in 2026.

04/20/2026, 6:00 AM • GlobeNewswire

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics, a radiopharmaceutical development company, announced that its senior leadership will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company is developing advanced cancer treatments using alpha-emitting isotope 212Pb with complementary imaging diagnostics, with programs in Phase 1/2a trials for neuroendocrine tumors, melanoma, and solid tumors.

04/02/2026, 7:00 AM • GlobeNewswire

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.

02/17/2026, 11:17 AM • Benzinga

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics, a radiopharmaceutical development company, announced it will report its full year 2025 financial results and provide a business update on March 16, 2025. The company is developing advanced cancer treatments using alpha-emitting isotope 212Pb with theranostic imaging capabilities, with multiple programs in Phase 1/2a trials.

02/17/2026, 7:00 AM • GlobeNewswire

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics will present updated data on its [212Pb]VMT-α-NET program at the ASCO Gastrointestinal Cancers Symposium in January 2026, highlighting promising safety and efficacy results for neuroendocrine tumor treatment.

12/04/2025, 7:00 AM • GlobeNewswire

Perspective Therapeutics to Participate in Upcoming December Conferences

Radiopharmaceutical company Perspective Therapeutics announced participation in upcoming healthcare conferences and highlighted its ongoing cancer treatment research using alpha-emitting isotope 212Pb technology.

11/20/2025, 7:00 AM • GlobeNewswire

Perspective Therapeutics to Participate in Upcoming November Conferences

Radiopharmaceutical company Perspective Therapeutics will participate in upcoming investor conferences, showcasing its advanced cancer treatment technology utilizing alpha-emitting isotope 212Pb for targeted radiation therapy.

10/31/2025, 7:00 AM • GlobeNewswire

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics plans to report Q3 2025 financial results on November 10, 2025, highlighting its radiopharmaceutical development progress in cancer treatments using alpha-emitting isotope 212Pb technology.

10/24/2025, 7:00 AM • GlobeNewswire

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.

07/23/2025, 9:26 AM • Benzinga

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics, a radiopharmaceutical company, will report its Q2 2025 financial results on August 13, 2025, focusing on advanced cancer treatments using alpha-emitting isotope 212Pb and developing complementary imaging diagnostics.

07/15/2025, 7:00 AM • GlobeNewswire

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics has reached alignment with the FDA to open the third dosing cohort of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors. The company is encouraged by the overall clinical profile observed at the second dose level and believes it is important to assess whether a higher dose could further improve the therapeutic profile.

06/21/2025, 8:00 AM • GlobeNewswire